November 19, 2026 · Kidney international · DOI: 10.1016/j.kint.2026.10.034

Secondary analysis of the FIELD randomized trial evaluated the performance of GFR slope in a non-glomerular model of estimated GFR decline.

Listen to this summary

This secondary analysis of the FIELD trial asked whether GFR slope measures can reliably predict clinical kidney outcomes when a drug causes an acute, non-glomerular eGFR dip, using fenofibrate as the test case. Fenofibrate produced an early eGFR decline of about 9 mL/min/1.73 m² and improved chronic slope but worsened total slope, while significantly increasing the clinical composite kidney endpoint (HR 1.48). The authors conclude that total slope and the conventional composite gave concordant treatment effects, though the abstract's mixed slope results and its harm signal make that concordance claim worth examining closely.

Alexandra Gallagher, Rachel L O'Connell, George Mangos, Brendan Smyth, Timothy M E Davis, Alicia J Jenkins, Russell S Scott, David Sullivan, Marja-Riitta Taskinen, Anthony C Keech, Meg J Jardine

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play